CellCentric

Cambridge, UK clinical-stage biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed/refractory multiple myeloma and other cancers. Based on the science of Azim Surani at the Gurdon Institute, Cambridge.